Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!
|
 veggie
Registered: 07/25/04
Posts: 13,985
Loc: 
|
 Headway in developing a faster-acting antidepressant
#7334803 - 08/25/07 10:15 PM (4 years, 9 months ago) |
|
|
August 25, 2007 - Los Angeles Times
Headway in developing a faster-acting antidepressant
The key might be provided by studying the effect that ketamine, an anesthetic, has on a neurotransmitter.
After years of little progress, scientists are making headway in the search for a better, faster-acting antidepressant. Experiments with an anesthetic called ketamine have yielded important clues about the biology of depression, leading scientists to attack the mood disorder in new ways.
Improved treatments are sorely needed. Depression affects about one in 10 adult Americans each year, while current drugs work in only 50% to 60% of patients, can cause sexual problems and take weeks to work. They also carry a small risk of suicidal thoughts and behaviors in adolescents and young adults.
All existing antidepressant drugs work in much the same manner. They act on a handful of neurotransmitters -- brain chemicals that pass messages along defined pathways -- that belong to a family called monoamines and circulate in a relatively small portion of the brain.
The most recognized of these neurotransmitters is serotonin, low levels of which have been linked to depression. Drugs such as Prozac and Celexa are aimed at raising serotonin levels available to the brain. The other transmitters targeted by antidepressants are dopamine and norepinephrine. Wellbutrin is an example of an antidepressant that boosts levels of these neurotransmitters but not serotonin.
Scientists first discovered these neurotransmitters affect depression in the 1950s when they found that the tuberculosis drug iproniazid also lifted patients' moods. The drug blocks an enzyme that converted serotonin, dopamine and norepinephrine into inactive forms, and after some study the drug was marketed for depression. Pharmaceutical companies have developed drugs targeting the trio of neurotransmitters ever since.
Because it is expensive to discover and develop new drugs, it is safer for pharmaceutical companies to stick with known biological targets than to head in risky new directions, said Dr. Carlos Zarate Jr., a researcher at the National Institute of Mental Health. As a result, "we have not made substantial gains in terms of antidepressants," Zarate said.
But recent studies on ketamine have pushed researchers to change how they think about depression. The anesthetic acts on glutamate, the brain's most plentiful neurotransmitter, which circulates widely in the brain and hasn't been linked to depression in the past.
In a small experiment led by Zarate last year, five of 18 people who received a single intravenous dose of ketamine experienced a dramatic lifting of their depression the first day and were still much better a week later. All patients in the experiment had first tried regular antidepressants but did not improve on them, according to the study published last August in the Archives of General Psychiatry.
Similar fast improvements were found in a study of eight patients conducted at Yale Medical School and published in Biological Psychiatry in 2000.
The rapid response was encouraging, Zarate said, suggesting that a faster-acting antidepressant may be possible. Current antidepressants take two to three weeks to begin working, and until recently, "it was just accepted as fact we couldn't do any better," he said.
Dr. Gerard Sanacora, director of the depression research program at Yale Medical School, said the results also mean that glutamate may have a more direct role in depression than serotonin and other brain chemicals targeted by current antidepressants.
"The fact that it acts so rapidly means that it is getting closer to the core of depression," Sanacora said.
In some ways, it's surprising that researchers studying depression didn't suspect the role of glutamine, which is an amino acid, in the disorder sooner. Malfunctions in the glutamate system have long been linked to other psychological and neurological disorders, including schizophrenia and Alzheimer's disease. Glutamate has long been associated with learning and memory.
"It is hard to image anything glutamate is not involved in," said Sanacora. "It is really what makes the brain run."
Still, scientists haven't yet figured out how the glutamate system goes awry in depression.
One theory is that glutamate leaks from brain cells, perhaps in response to chronic emotional stress, and causes changes in key brain structures.
The hippocampus, which processes memory, and the parts of the cortex, where decisions are made, are known to be smaller in depressed people. Perhaps, Zarate said, excess glutamate caused cells in these brain structures to shrivel. High amounts of glutamate are toxic to brain cells and cause the death of some neurons in stroke patients, he noted.
Ketamine is not approved for treating depression and Zarate said it was too soon to give it to patients outside the confines of a clinical trial.
Ketamine can cause hallucinations and confusion and is sometimes abused as a club drug. In fact, he said, all patients who received the drug in his study reported out-of-body hallucinations.
But studying the workings of ketamine in the brain may provide researchers with information that could lead to a new class of fast-acting antidepressants.
Zarate and colleagues reported last month that ketamine blocks a glutamate receptor, called NMDA, on the surface of nerve cells.
As a result, glutamate can't bind to it anymore and instead binds and activates another receptor, called AMPA. The increased activity of AMPA is what produces ketamine's mood-elevating effects, Zarate concluded.
Drawing an analogy, he explained: "If you imagine a bifurcated garden hose and you block the left nozzle, you will get a massive amount of water through the right."
A number of drugs that work on glutamate have been approved as treatments for neurological disorders and are now being tested against depression.
Among them are Forest Laboratories' Namenda, which is approved to treat Alzheimer's disease symptoms, and Sanofi-Aventis' Rilutek, which is used to slow amyotrophic lateral sclerosis, or Lou Gehrig's disease.
Neither is expected to be a big breakthrough. Namenda is not a powerful blocker of the NMDA receptor and Rilutek doesn't work very quickly.
Zarate's group at the National Institute of Mental Health is planning a trial in which depressed patients will receive a dose of ketamine, followed by regular doses of Rilutek, which scientists hope will maintain patients' recovery.
Other drugs targeting glutamate are on the way, although it could be many years before they reach patients. For example, an experimental Merck & Co. drug that blocks a sub-unit of the NMDA receptor is now in clinical trials.
In May, Pfizer Inc. reported on a study of 30 depressed patients who received an experimental intravenous drug that also blocks that same sub-unit of the NMDA receptor.
The antidepressive effect of the drug, CP-101,606, was similar to that of ketamine, said Dr. Sheldon H. Preskorn, chairman of the department of psychology and behavioral sciences at the University of Kansas School of Medicine-Wichita, who led the study.
Within 24 hours, more than half of the patients in the study had a "bright affect," were smiling spontaneously and talked more rapidly, Preskorn said. Their about-face was so remarkable "that had I not seen it myself, I would not have believed it," Preskorn said.
Many questions remain.
No one knows whether depressed patients will tolerate or respond to a second dose of a ketamine-like drug. Patients in trials so far have received only one dose.
In addition, the rapid personality overhauls induced by the drugs have implications for family and social relationships that will need to be addressed, probably through counseling or therapy, Preskorn said.
"The drugs deal with the hardware problem," he said.
"Once that's done, we still have to deal with the software issue."
|
 Puck
Stranger
Registered: 08/01/07
Posts: 55
Last seen: 3 years, 11 months
|
Re: Headway in developing a faster-acting antidepressant [Re: veggie]
#7335105 - 08/26/07 12:18 AM (4 years, 9 months ago) |
|
|
Disgusting.
--------------------
“Watching television is like taking black spray paint to your third eye.”-Bill Hicks
|
CaptainLinger
A Fungus Amongus
Registered: 05/25/07
Posts: 1,756
Last seen: 4 years, 4 months
|
Re: Headway in developing a faster-acting antidepressant [Re: Puck]
#7335162 - 08/26/07 12:42 AM (4 years, 9 months ago) |
|
|
Really? We're all biological machines. Might as well make the ride bearable 
|
John Smith
Solo Voyager
Registered: 05/22/07
Posts: 532
Last seen: 3 years, 7 months
|
Re: Headway in developing a faster-acting antidepressant [Re: CaptainLinger]
#7335420 - 08/26/07 04:19 AM (4 years, 9 months ago) |
|
|
what is disgusting is that pharms that make you happy are approved and promoted,while plants (or "illegal" chems) that make you happy put you in jail.
--------------------
I have no idea what I am talking about but I do know I say things you don't understand and if you do understand what I am saying then you are wrong.
|
poke smot!
cognitive consonance
Registered: 01/08/03
Posts: 4,669
|
Re: Headway in developing a faster-acting antidepressant [Re: John Smith]
#7339269 - 08/27/07 08:23 AM (4 years, 9 months ago) |
|
|
Agreed, there are many natural alternatives out there which will never be researched because they do not have the same potential for profit as other drugs, even if the natural alternatives have been shown to be more efficacious or more safe. Take for example red yeast rice, just as effective as lipitor or other statins, but potentially safer. Actually, lipitor and these statin drugs are a great example of trying to switch patients to newer, more costly (read: profitable) drugs which may be less effective, for the sake of money. ("The new purple pill!")
In the case of "new" antidepressants, I've had mine for years and it's legal. In fact it has quite a history of human use among indo-european cultures. The drug I speak of is harmala, containing the beta-carbolines harmine, harmaline, and others. Harmala is an MAOI similar to other antidepressants (though the pharmaceutical MAOIs tend to be less safe with food restrictions and all); also, these compounds are NMDA partial antagonists, just what this article has been discussing.
If NMDA receptor blockage is a more effective route of antidepressing, then that will be where new drugs target. Once the patented SSRIs all go generic the pharmaceutical companies will need new, novel compounds to patent.
It is unfortunate, though, that things like harmala will never see research, unless the aim of the research is to find a synthetic "novel" patentable compound that is like harmaline. Mother nature seems to do best though.
It seems illogical with Big Pharma. I mean, wouldn't it be best to use nature's version, the one that works best, the one that has quie a history of use? Or, would it be better to make an un-natural synthetic version which might have negative side-effects or unknown long-term effects, and spend millions on the clinical trials, just so in the end it can be sold at huge markups?
It is unfortunate, but I think that some day we will be finding ourselves in a situation where, one of these unnatural drugs will have some devastating long-term side-effects (fen-phen comes to mind) that aren't discovered until it's too late for millions of patients, and it will be painfully obvious that the natural counterpart from which the synthetic was derived, was just as effective, much safer, and as expensive as the soil it's growing on. And when that happens we'll realize we shot ourselves in the foot by letting these profit-driven companies decide the fate of our healthcare.
I can also forsee natural alternatives being scheduled (harmala will be one) once similar drugs come out on the market that have a similar structure/effects. If Big Pharma had their way, every vitamin, mineral, and supplement would be controlled and only the remedies of interest to "them" will be available.
--------------------
 
|
CaptainLinger
A Fungus Amongus
Registered: 05/25/07
Posts: 1,756
Last seen: 4 years, 4 months
|
Re: Headway in developing a faster-acting antidepressant [Re: poke smot!]
#7339360 - 08/27/07 08:52 AM (4 years, 9 months ago) |
|
|
MAOIs all have the same path of action, and if you don't think harmala has the same food restrictions, you're in for a very unpleasant surprise. Go ahead, eat 5 pounds of cheese...
The natural alternatives have been known, and studied. Certainly there are a lot more on the way. These drugs are using techniques not found naturally, and seem to work better than anything we have.
You're also talking about research being done, federally funded, to mimic or incorporate drugs that are *currently* scheduled. The drug industry has a lot of internal contradiction of its stated goals, but it's not some Orwell shit like you suggest
|
poke smot!
cognitive consonance
Registered: 01/08/03
Posts: 4,669
|
Re: Headway in developing a faster-acting antidepressant [Re: CaptainLinger]
#7339418 - 08/27/07 09:11 AM (4 years, 9 months ago) |
|
|
Quote:
CaptainLinger said:
MAOIs all have the same path of action, and if you don't think harmala has the same food restrictions, you're in for a very unpleasant surprise. Go ahead, eat 5 pounds of cheese...
Check. Maybe I tolerate tyramine well, or maybe tyramine has more affinity for MAO because harmala is reversible and only inhibits MAO-A.
I'm not proposing 'orwellian' theories. I am just saying that when these 'new' antidepressants are being developed, 'they' won't be looking at the things that exist out there in nature except to try to mimic it.
I guess I also want to someday see that harmaline as an NMDA antagonist antidepressant, is safer/more effective/better than any synthetic version being made, as if the synthetic version is being made "just because" the natural alternative will not suffice for their business model.
--------------------
|
Divided_Sky
Ten ThousandThings
Registered: 11/02/03
Posts: 3,171
Loc: The Shining Void
Last seen: 4 years, 1 day
|
Re: Headway in developing a faster-acting antidepressant [Re: poke smot!]
#7340252 - 08/27/07 11:04 AM (4 years, 9 months ago) |
|
|
I think these scientists are not understanding why ketamine works to stop depression. Because of the biochemical bent of modern psychology they assume that neurotransmitters must be the reason, but it's almost like they forgot they were giving people huge doses of KETAMINE. Not sugar pills. These experiences change the mind, not just brain chemistry.
I can say a similar thing about LSD, every time I take it I feel completely non-depressed for 2 weeks to a month after. Is that because it messed with my brain receptors or the experience itself? I believe it is the latter, and it just takes that long for old habbits to start re-emerging (albeit weaker than before).
Dissociatives are different, of course. I have never used ketamine but if it works like nitrous oxide then it seems pretty obvious how it would lift depression, if not the trip itself. Nitrous always seems to be like a reset switch and whatever is bothering me is disengaged so I can start anew. What they are doing with ketamine is probobly like electroshock without the brain damage.
--------------------
1. "After an hour I wasn't feeling anything so I decided to take another..."
2. "We were feeling pretty good so we decided to smoke a few bowls..."
3. "I had to be real quiet because my parents were asleep upstairs..."
| |
|
|
You cannot start new topics / You cannot reply to topics
HTML is disabled / BBCode is enabled
Moderator: veggie
745 topic views. 9 members, 88 guests and 1 web crawlers are browsing this forum.
[ Toggle Favorite | Print Topic ]
| | |
|
|
|
Previous
Index
Next
Threaded
Shop for: 
Edit 
Reply 
